Global Pharmerging Markets 2017-2021

Table of Contents

PART 01: Executive summary

PART 02: Scope of  the report

• Market overview

PART 03: Market research methodology

• Research methodology
• Economic indicators

PART 04: Introduction

• Key market highlights
• Highlights

PART 05: Global pharmaceutical market

• Market size and forecast

PART 06: Road to pharmerging markets

PART 07: Pharmerging markets

PART 08: Market landscape

• Medicine spending in emerging economies
• Five forces analysis

PART 09: Market segmentation  by geography

PART 10: Market overview of tier I countries

• China

PART 11: Market overview of tier II countries

• Brazil
• Russia
• India

PART 12: Market overview of tier III countries

• Market size and forecast

PART 13: Market drivers

• Limitations in developed economies fuels demand in emerging economies
• Increasing focus toward biosimilar in potential areas
• Expansion initiatives of vendors

PART 14: Impact of drivers

PART 15: Market challenges

• IP protection issues
• Socio-political issues in cross geography transactions
• Stringent price control and generic-centric usage lead to value erosion

PART 16: Impact of drivers and challenges

PART 17: Market trends

• Potential of new countries in emerging markets
• Positive outlook toward adoption of targeted therapies
• Evolving stakeholder landscape to change market dynamics

PART 18: Vendor landscape

• Competitive scenario

PART 19: Key vendor analysis

• AstraZeneca
• GlaxoSmithKline
• Pfizer
• Sanofi
• Novartis
• Other prominent vendors

PART 20: Appendix

• List of Abbreviations

PART 21: Explore Technavio